# Phase 2 Study of NX9 for Delineation of Bowel Anatomy

> **NCT04789200** · PHASE2 · COMPLETED · sponsor: **Nextrast, Inc.** · enrollment: 32 (actual)

## Conditions studied

- GI Carcinoma
- GI Disorders

## Interventions

- **DRUG:** NX9 Oral Contrast Agent

## Key facts

- **NCT ID:** NCT04789200
- **Lead sponsor:** Nextrast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789200, "Phase 2 Study of NX9 for Delineation of Bowel Anatomy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04789200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*